Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Estradiol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 5/20 | 0.89 |
| ▸ | LMNA | P02545 | 5/20 | 0.89 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.89 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.89 |
| ▸ | TSHR | P16473 | 2/20 | 0.89 |
| ▸ | STS | P08842 | 2/20 | 0.89 |
| ▸ | PGR | P06401 | 2/20 | 0.89 |
| ▸ | AR | P10275 | 2/20 | 0.89 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.89 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.89 |
| ▸ | MEN1 | O00255 | 2/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.89 |
| ▸ | MAPT | P10636 | 2/20 | 0.89 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.89 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.89 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.89 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.89 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.89 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.89 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alfatradiol SCHEMBL504619 | 1.00 | ESR1 (0.89) | ESR1LMNAHSD17B10ESR2TSHR | |
| Estradiol SCHEMBL231200 | 1.00 | ESR1 (0.89) | ESR1LMNAHSD17B10ESR2TSHR | |
| Estradiol SCHEMBL28291281 | 0.99 | HSD17B10 (0.87) | ESR1LMNAHSD17B10ESR2TSHR | |
| Estradiol SCHEMBL6409242 | 0.99 | HSD17B10 (0.87) | ESR1LMNAHSD17B10ESR2TSHR | |
| Alfatradiol SCHEMBL14562872 | 0.99 | HSD17B10 (0.87) | ESR1LMNAHSD17B10ESR2TSHR | |
| Alfatradiol SCHEMBL28291280 | 0.99 | HSD17B10 (0.87) | ESR1LMNAHSD17B10ESR2TSHR | |
| Estradiol SCHEMBL628175 | 0.96 | ESR1 (0.85) | ESR1LMNAHSD17B10ESR2TSHR | |
| Estradiol SCHEMBL24037697 | 0.94 | ESR1 (1.00) | ESR1LMNAHSD17B10ESR2TSHR | |
| Estradiol SCHEMBL7037626 | 0.94 | ESR1 (1.00) | ESR1LMNAHSD17B10ESR2TSHR | |
| Estradiol SCHEMBL19235633 | 0.94 | ESR1 (1.00) | ESR1LMNAHSD17B10ESR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 329 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4079308-A1 | MASS SPECTROMETRY ASSAY FOR ESTROGENIC COMPOUNDS | Quest Diagnostics Investments Incorporated (US) | 2022-10-26 | — | — | EP | claimed |
| US-10837971-B2 | Mass spectrometry assay for estrogenic compounds during hormone replacement therapy | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2020-11-17 | — | — | US | claimed |
| EP-2807482-B1 | ANALYSIS OF ESTRADIOL AND ANALYTES WITH PHENOLIC OH USING LABELING CHEMISTRY AND LC-MSMS WORKFLOW | DH TECHNOLOGIES DEV PTE LTD (SG) | 2018-03-14 | — | — | EP | claimed |
| US-9874575-B2 | Analysis of estradiol and analytes with phenolic OH using labeling chemistry and LC-MSMS workflow | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2018-01-23 | — | — | US | claimed |
| CN-104040332-B | There is phenol system OH estradiol and analyte using mark chemistry and LC MSMS workflow analysis | DH科技发展私人贸易有限公司 | 2017-10-20 | — | — | CN | claimed |
| US-20160377636-A1 | MASS SPECTROMETRY ASSAY FOR ESTROGENIC COMPOUNDS | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED | 2016-12-29 | — | — | US | claimed |
| US-20150051111-A1 | ANALYSIS OF ESTRADIOL AND ANALYTES WITH PHENOLIC OH USING LABELING CHEMISTRY AND LC-MSMS WORKFLOW | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2015-02-19 | — | — | US | claimed |
| EP-2807482-A1 | ANALYSIS OF ESTRADIOL AND ANALYTES WITH PHENOLIC OH USING LABELING CHEMISTRY AND LC-MSMS WORKFLOW | Dh Technologies Development Pte. Ltd. (SG) | 2014-12-03 | — | — | EP | claimed |
| CN-104040332-A | Analysis of estradiol and analytes with phenolic OH using labeling chemistry and LC-MSMS workflow | DH TECHNOLOGIES DEV PTE LTD | 2014-09-10 | — | — | CN | claimed |
| WO-2013108113-A1 | ANALYSIS OF ESTRADIOL AND ANALYTES WITH PHENOLIC OH USING LABELING CHEMISTRY AND LC-MSMS WORKFLOW | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2013-07-25 | — | — | WO | claimed |
| WO-2010075175-A1 | MASS SPECTROMETRY ASSAY FOR ESTROGENIC COMPOUNDS | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2010-07-01 | — | — | WO | claimed |
| US-20100155594-A1 | MASS SPECTROMETRY ASSAY FOR ESTROGENIC COMPOUNDS | QUEST DIAGNOSTICS INVESTMENTS LLC | 2010-06-24 | — | — | US | claimed |
| US-20100075991-A1 | Post-translational regulation of catalytic activities of cytochrome P450 46A1 and uses thereof | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, THE | 2010-03-25 | — | — | US | claimed |
| WO-2009100871-A2 | DRUG DELIVERY SYSTEM WITH STABILISING EFFECT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-08-20 | — | — | WO | claimed |
| WO-2009101021-A2 | ESTRADIOL-CONTAINING DRUG DELIVERY SYSTEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-08-20 | — | — | WO | claimed |
| WO-2008153722-A1 | POST-TRANSLATIONAL REGULATION OF CATALYTIC ACTIVITIES OF CYTOCHROME P450 46A1 AND USES THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-12-18 | — | — | WO | claimed |
| EP-1814526-A2 | ORAL SOLID DOSAGE FORMS CONTAINING A LOW DOSE OF ESTRADIOL | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-08-08 | — | — | EP | claimed |
| US-20060111334-A1 | Oral solid dosage forms containing a low dose of estradiol | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-25 | — | — | US | claimed |
| WO-2006048261-A2 | ORAL SOLID DOSAGE FORMS CONTAINING A LOW DOSE OF ESTRADIOL | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-11 | — | — | WO | claimed |
| US-5830767-A | WICKING CORE AND SHEATH | AT POINT BIO (US) | 1998-11-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075991-A1 | Post-translational regulation of catalytic activities of cytochrome P450 46A1 and uses thereof | CYP46A1, CYP11A1, CYP27A1 | ESR1 3835/4885LMNA 3648/4885HSD17B10 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.